FMP

FMP

Enter

IDYA - IDEAYA Biosciences, ...

photo-url-https://images.financialmodelingprep.com/symbol/IDYA.png

IDEAYA Biosciences, Inc.

IDYA

NASDAQ

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

23.14 USD

-0.01 (-0.04322%)

IDYA Financial Statements

Year

2023

2022

2021

2020

Total Revenue

23.39M

50.93M

27.94M

19.54M

Cost of Revenue

4.01M

2.1M

1.73M

39.7M

Gross Profit

19.38M

48.83M

26.22M

-20.16M

Operating Expenses

157.81M

113.43M

78.21M

54.88M

Research and Development

129.51M

89.54M

58.16M

39.7M

Selling, General & Administrative Expenses

28.31M

23.9M

20.05M

15.18M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

28.31M

23.9M

20.05M

15.18M

Other Expenses

0

0

0

0

Operating Income

-134.43M

-62.5M

-50.27M

-35.34M

Total Other Income/Expenses Net

21.47M

3.85M

506k

849k

Income Before Tax

-112.96M

-58.66M

-49.76M

-34.49M

Income Tax

0

-3.85M

-2.23M

-2.23M

Net Income

-112.96M

-54.81M

-47.53M

-32.27M

Basic EPS

-1.96

-1.32

-1.35

-1.31

EPS Diluted

-1.96

-1.32

-1.35

-1.31

Basic Average Shares

57.52M

41.44M

35.25M

24.72M

Diluted Average Shares

57.52M

41.44M

35.25M

24.72M

EBITDA

-130.42M

-60.4M

-48.54M

-33.96M

Retained Earning Schedule

Year

2023

2022

2021

2020

Retained Earnings (Previous Year)

-235.4M

-176.75M

-126.99M

-92.49M

Net Income

-112.96M

-54.81M

-47.53M

-32.27M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-348.36M

-235.4M

-176.75M

-126.99M

Other Distributions

-112.96M

-58.66M

-49.76M

-34.49M

PPE Schedule

Year

2023

2022

2021

2020

Gross PPE

8.41M

8.99M

8.66M

9.48M

Annual Depreciation

4.01M

2.1M

1.73M

1.38M

Capital Expenditure

-2.37M

-3.44M

-2.64M

-493k

Net PPE

6.77M

10.34M

9.58M

8.59M

Intangible and Goodwill Schedule

Year

2023

2022

2021

2020

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep